Maria Bell, MD
Gynecologic Oncology · Sioux Falls, SDNPI 1174529929
Payments from drug & device makers
Across 568 payments — averaging $9987.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$5M
- Genentech, Inc.$234K
- Novocure Inc.$98K
- Eli Lilly$88K
- AbbVie$70K
- GSK$57K
- plus $109K from 22 others
What the payments were for
- Consulting fees$36,34855%
- Speaking & faculty fees$23,45036%
- Travel & lodging$3,7466%
- Food & beverage$1,9243%
- Education$1390%
- Gifts$2460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 315 | $5,016,774 |
| Genentech, Inc. | 57 | $234,443 |
| Novocure Inc. | 39 | $98,204 |
| Eli Lilly | 5 | $87,505 |
| AbbVie(2 entities) | 12 | $70,475 |
| GSK | 19 | $56,510 |
| Daiichi Sankyo Inc. | 42 | $28,581 |
| Astrazeneca UK Limited | 2 | $20,400 |
| Tesaro, Inc. | 24 | $19,056 |
| E.r. Squibb & Sons, L.L.C. | 3 | $15,501 |
| AstraZeneca | 7 | $13,284 |
| Virtual Incision Corporation | 10 | $9,153 |
| Seagen Inc. | 3 | $1,646 |
| Intuitive Surgical | 2 | $258 |
| Incyte Corporation | 2 | $221 |
| Bayer | 1 | $143 |
| Eisai Inc. | 6 | $121 |
| Clovis Oncology, Inc. | 1 | $85 |
| Myriad Genetic Laboratories, Inc. | 4 | $71 |
| Pfizer | 3 | $68 |
| Monaghan Medical Corporation | 1 | $50 |
| Hologic Sales And Service, LLC | 2 | $49 |
| AVEO Pharmaceuticals, Inc. | 3 | $46 |
| Northgate Technologies, Inc. | 1 | $37 |
| Baxter Healthcare | 1 | $25 |
| Galderma Laboratories, L.p. | 1 | $20 |
| Novartis | 1 | $20 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few gynecologic oncology providers in South Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamoxifen Citrate | 16 | $1,074 |
| Letrozole | 12 | $271 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Sioux Falls
- David StarksSioux Falls$4.3M
- Luis Rojas-EspaillatSioux Falls$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.